Literature DB >> 28822906

The impact of HTLV-1 on the cellular genome.

Lucy Cook1, Anat Melamed2, Hiroko Yaguchi2, Charles Rm Bangham3.   

Abstract

Human T-lymphotropic virus type-1 (HTLV-1) is the causative agent of adult T-cell leukaemia/lymphoma (ATL), an aggressive CD4+ T-cell malignancy. The mechanisms of leukaemogenesis in ATL are incompletely understood. Insertional mutagenesis has not previously been thought to contribute to the pathogenesis of ATL. However, the recent discovery that HTLV-1 binds the key chromatin architectural protein CTCF raises the hypothesis that HTLV-1 deregulates host gene expression by causing abnormal chromatin looping, bringing the strong HTLV-1 promoter-enhancer near to host genes that lie up to 2Mb from the integrated provirus. Here we review current opinion on the mechanisms of oncogenesis in ATL, with particular emphasis on the local and distant impact of HTLV-1 on the structure and expression of the host genome.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28822906     DOI: 10.1016/j.coviro.2017.07.013

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  13 in total

1.  Short- and long-range cis interactions between integrated HPV genomes and cellular chromatin dysregulate host gene expression in early cervical carcinogenesis.

Authors:  Ian J Groves; Emma L A Drane; Marco Michalski; Jack M Monahan; Cinzia G Scarpini; Stephen P Smith; Giovanni Bussotti; Csilla Várnai; Stefan Schoenfelder; Peter Fraser; Anton J Enright; Nicholas Coleman
Journal:  PLoS Pathog       Date:  2021-08-25       Impact factor: 6.823

2.  Successfully treated acute adult T-cell leukemia with haploidentical stem cell transplantation.

Authors:  Aswani Thurlapati; Christopher Graham; Kyle Boudreaux; Tamna Wangjam
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-04-12

3.  Molecular fusion events in carcinogenic organisms: a bioinformatics study for the detection of fused proteins between viruses, bacteria and eukaryotes.

Authors:  Eleni Papakonstantinou; Kalliopi Io Diakou; Thanasis Mitsis; Konstantina Dragoumani; Flora Bacopoulou; Vasilis Megalooikonomou; Sophia Kossida; George P Chrousos; Dimitrios Vlachakis
Journal:  EMBnet J       Date:  2022-04-04

Review 4.  HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.

Authors:  Nicolas Futsch; Renaud Mahieux; Hélène Dutartre
Journal:  Viruses       Date:  2017-12-21       Impact factor: 5.048

Review 5.  Viral Oncology: Molecular Biology and Pathogenesis.

Authors:  Uyen Ngoc Mui; Christopher T Haley; Stephen K Tyring
Journal:  J Clin Med       Date:  2017-11-29       Impact factor: 4.241

Review 6.  HTLV Deregulation of the NF-κB Pathway: An Update on Tax and Antisense Proteins Role.

Authors:  Stefania Fochi; Simona Mutascio; Umberto Bertazzoni; Donato Zipeto; Maria G Romanelli
Journal:  Front Microbiol       Date:  2018-02-21       Impact factor: 5.640

Review 7.  The Double-Edged Sword Role of Viruses in Gastric Cancer.

Authors:  Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Rafał Hrynkiewicz; Mikołaj Wołącewicz; Rafał Becht; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

Review 8.  p30 protein: a critical regulator of HTLV-1 viral latency and host immunity.

Authors:  Ramona Moles; Sarkis Sarkis; Veronica Galli; Maria Omsland; Damian F J Purcell; David Yurick; Georges Khoury; Cynthia A Pise-Masison; Genoveffa Franchini
Journal:  Retrovirology       Date:  2019-12-18       Impact factor: 4.602

9.  Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas.

Authors:  Peng Wang; Yanwei Liu; Lin Zhi; Xiaoguang Qiu
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

Review 10.  HTLV-1: Regulating the Balance Between Proviral Latency and Reactivation.

Authors:  Anurag Kulkarni; Charles R M Bangham
Journal:  Front Microbiol       Date:  2018-03-19       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.